Anzeige
Meldung des Tages: Milliardenmarkt, eigene KI-Plattform, starke Kasse: Ist diese Aktie massiv unterbewertet?

Sanofi

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF Branche:  Pharmazeutika Land:  Frankreich
81,41 €
+0,03 €
+0,04%
21:36:38 Uhr
Depot/Watchlist
Marktkapitalisierung *
102,65 Mrd. €
Streubesitz
43,33%
KGV
10,68
Dividende
3,92 EUR
Dividendenrendite
4,76%
Nachhaltigkeits-Score
68 %
Index-Zuordnung
Euro Stoxx 50
Weiter aufwärts? Long handeln - Jetzt mit Hebel 7,02: MK5GKW
Werbung

Ad-hocs

17.06.25 - GlobeNewswire
Press release: Sanofi successfully prices €1.5 billion bond issue
Sanofi successfully prices €1.5 billion bond issue
15.06.25 - GlobeNewswire
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-​ever presented phase 4 ...
09.06.25 - GlobeNewswire
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus ...
05.06.25 - GlobeNewswire
Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
Sanofi Launches 2025 Global Employee Stock Purchase Plan
03.06.25 - GlobeNewswire
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
ASCO: new Sarclisa data support subcutaneous administration with on-body injector
03.06.25 - GlobeNewswire
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare diseases Under regulatory review in the US, ...
30.05.25 - GlobeNewswire
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe ...
29.05.25 - GlobeNewswire
Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
Beyfortus public health advantage bolstered by first real-​world comparison of infant vs maternal RSV immunization programs Late-​breaking data show infant respiratory syncytial ...
27.05.25 - GlobeNewswire
Press Release: Sanofi completes acquisition of DR-0201
Sanofi completes acquisition of DR-0201
22.05.25 - GlobeNewswire
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today ...
30.04.25 - GlobeNewswire
Press Release: Annual General Meeting of April 30, 2025
Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024 Distribution of a cash dividend of €3.92 per share, with payment as of May 14, ...
30.04.25 - GlobeNewswire
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Sanofi and CD&R close Opella transaction, creat e global consumer healthcare leader Paris, April 30, 2025 . Opella today becomes an independent global leader in consumer ...
24.04.25 - GlobeNewswire
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales ...
18.04.25 - GlobeNewswire
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent ...
15.04.25 - GlobeNewswire
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous ...
08.04.25 - GlobeNewswire
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in ...
03.04.25 - GlobeNewswire
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-...
28.03.25 - GlobeNewswire
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-​lowering therapy in hemophilia, offers ...
28.03.25 - GlobeNewswire
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-​ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal ...
26.03.25 - GlobeNewswire
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to ...

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »